CV Sciences, Inc. (CVSI) Earnings Call Transcripts

CV Sciences, Inc.'s Latest Earnings Call - June 2, 2026

In the Q1 2026 earnings call for CV Sciences, Inc., management highlighted ongoing regulatory challenges impacting the hemp industry, particularly the potential implications of the 2025 Appropriations Act. Revenue pressures are expected to persist as the company navigates uncertain federal guidelines. While specific financial metrics were not disclosed, management emphasized their commitment to operational efficiency and product innovation as key strategies moving forward, indicating a focus on long-term growth despite current headwinds.

Reported metrics

Guidance from management

Management indicated that revenue pressures are expected to continue due to regulatory uncertainties, but they are committed to maintaining operational efficiency and pursuing product innovation as part of their long-term strategy.

What management said

Thank you. At this time, I am appointing Mr. Grasser to act as Inspector of Election at this meeting. Mr. Grasser has taken and subscribed the customary oath of office to execute his duties with strict impartiality. We will file this oath with the records of the meeting. His function is to decide upon the qualifications of voters present at this meeting accept their votes and when balloting on all matters is complete...

I have been informed that proxies have been received for 116,234,784 million of the 193458,420 shares of common stock outstanding on the record date, which represents approximately 60.1% of the total number of outstanding shares. This constitutes a quorum for the meeting today, and we may now carry out the official business of the meeting.

What analysts pressed on

Analysts expressed concerns regarding the potential revenue impact of the 2025 Appropriations Act and the uncertainty surrounding federal regulations. There were questions about how these factors could affect product offerings and overall market positioning.

Main topics on the call

• Regulatory Environment Impact — Management discussed the potential implications of the 2025 Appropriations Act, stating it could 'require us to pivot away from certain products resulting in revenue headwinds.' They outlined three scenarios regarding th...
• Cost Structure and Operational Efficiency — Management emphasized their focus on maintaining 'strict discipline over our cost structure and operational efficiency,' noting that they have streamlined operations to near breakeven levels. This approach is intended to...
• Product Innovation and Diversification — The company plans to 'continue to invest aggressively in product innovation,' particularly in developing hemp-derived products that comply with regulations. Additionally, they are expanding their Plus Health brand to div...
• International Expansion — Management highlighted the importance of their European subsidiary, Cultured Foods, stating it will play a crucial role in 'new product launches beginning in 2026.' This expansion is part of their strategy to tap into in...

Read the full CV Sciences, Inc. transcript (June 2, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 28 CV Sciences, Inc. earnings call transcripts on record, spanning March 16, 2020 to June 2, 2026. Based on this history, CV Sciences, Inc. reports quarterly. The most recent call on file is dated June 2, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

CVSI

Exchange

OTCPK

Country

US

Sector

Consumer Staples

Industry

Personal Care Products

Calls on record

28

First call

March 16, 2020

Most recent

June 2, 2026

Reporting cadence

quarterly